M&A Deal Summary

AxoSim Acquires StemoniX

On July 17, 2023, AxoSim acquired life science company StemoniX from Vyant Bio

Acquisition Highlights
  • This is AxoSim’s 1st transaction in the Life Science sector.
  • This is AxoSim’s 1st transaction in the United States.
  • This is AxoSim’s 1st transaction in Minnesota.

M&A Deal Summary
Date 2023-07-17
Target StemoniX
Sector Life Science
Buyer(s) AxoSim
Sellers(s) Vyant Bio
Deal Type Divestiture

Target

StemoniX

Maple Grove, Minnesota, United States
StemoniX engages in developing high-throughput disease-specific human organoid platforms integrated with leading-edge data science technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. StemoniX is based in Maple Grove, Minnesota.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AxoSim

New Orleans, Louisiana, United States
Category Company
Sector Information Technology
DESCRIPTION

AxoSim is a provider of drug discovery platforms NerveSim® and BrainSim® deliver clinically-relevant data enabling selection of better lead candidates with phenotypically accurate assays. AxoSim is based in New Orleans, Louisiana.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Minnesota) 1 of 1
Country (United States) 1 of 1
Year (2023) 1 of 1

Seller(S) 1

SELLER

Vyant Bio

Cherry Hill, New Jersey, United States
Category Company
Founded 1999
Sector Life Science
Employees34
Revenue 1M USD (2021)
DESCRIPTION

Vyant Bio is a drug discovery and preclinical oncology DNA-based cancer diagnostics and services medical institutions around the world. Vyant Bio's tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital, and HPV-associated cancers. Vyant Bio also offers a range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Vyant Bio was founded in 1999 and is based in Cherry Hill, New Jersey.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
State (Minnesota) 1 of 1
Country (United States) 2 of 2
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-24 StemoniX

Maple Grove, Minnesota, United States

StemoniX engages in developing high-throughput disease-specific human organoid platforms integrated with leading-edge data science technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. StemoniX is based in Maple Grove, Minnesota.

Buy -
Mergr

Product

Company

Legal